Table 3.
Overview of in vitro neutralizing activity (IC50 and IC90) toward SARS-CoV-2 prototype (D614G), beta, gamma, delta, and omicron for the top eight mAbs and four commercial mAbs
| Antibody | Neutralization (nM) |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| D614G |
Beta |
Gamma |
Delta |
Omicron |
||||||
| IC50 | IC90 | IC50 | IC90 | IC50 | IC90 | IC50 | IC90 | IC50 | IC90 | |
| 1A10 | 0.74 | 4.06 | 1.49 | 6.91 | 0.43 | 4.67 | 1.25 | 7.36 | / | / |
| 1C1 | 0.58 | 3.75 | 1.52 | 6.98 | 0.37 | 4.15 | 1.02 | 5.68 | / | / |
| 1C11 | 0.16 | 0.82 | 7.41 | 259.53 | 0.74 | 44.83 | / | / | / | / |
| 2B11 | 0.62 | 2.06 | / | / | / | / | / | / | / | / |
| 2B2 | 0.17 | 1.23 | 7.26 | 100.60 | 0.77 | 19.63 | 3.68 | 23.91 | 5.58 | 39.87 |
| 2D6 | 0.57 | 4.61 | 1.51 | 7.32 | 0.39 | 3.97 | 0.93 | 4.80 | / | / |
| 3B8 | 0.016 | 0.068 | 0.030 | 0.10 | 0.006 | 0.028 | 0.020 | 0.12 | 0.015 | 0.10 |
| 3E6 | 0.32 | 3.28 | 0.14 | 1.43 | 0.04 | 0.38 | 1.07 | 6.89 | 7.43 | 261.21 |
| REGN10933 | 0.034 | 0.30 | 10.85 | 143.08 | 1.42 | 25.00 | 0.055 | 0.19 | / | / |
| REGN10987 | 0.026 | 0.28 | 0.074 | 0.72 | 0.007 | 0.080 | 0.25 | 3.56 | / | / |
| Ly-CoV555 | 0.036 | 0.18 | / | / | / | / | / | / | / | / |
| Ly-CoV016 | 0.25 | 3.87 | / | / | / | / | 0.10 | 0.57 | / | / |
Neutralizing activity (IC50 and IC90; in nM) was determined via VSV pseudotyped assay. / = no neutralizing activity when tested at a concentration of 33.34 nM. IC90 values >33.34 nM are obtained via extrapolation of the neutralization curves.